PMC:7195088 / 15597-15766 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"655","span":{"begin":107,"end":115},"obj":"Species"},{"id":"735","span":{"begin":61,"end":80},"obj":"Chemical"},{"id":"736","span":{"begin":85,"end":103},"obj":"Chemical"},{"id":"908","span":{"begin":126,"end":134},"obj":"Disease"}],"attributes":[{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"Tax:9606"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"MESH:C558899"},{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"MESH:D006886"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recr"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":126,"end":134},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"d randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T54","span":{"begin":33,"end":35},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T55","span":{"begin":41,"end":43},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T56","span":{"begin":141,"end":146},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"d randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T87","span":{"begin":61,"end":80},"obj":"Chemical"},{"id":"T88","span":{"begin":61,"end":70},"obj":"Chemical"},{"id":"T89","span":{"begin":71,"end":80},"obj":"Chemical"},{"id":"T90","span":{"begin":85,"end":103},"obj":"Chemical"},{"id":"T91","span":{"begin":141,"end":146},"obj":"Chemical"}],"attributes":[{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"d randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recr"}

{"project":"2_test","denotations":[{"id":"32360444-32187464-22369752","span":{"begin":41,"end":43},"obj":"32187464"}],"text":"d randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recr"}